NeuroPhage Pharmaceuticals Has Positive Results With Neurodegenerative Disease Therapy

Many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and ALS, are characterized by aggregates of proteins. Many companies have tried to target the disassembly of these protein aggregates; however, few have made progress using this approach, until now. Cambridge, MA-based NeuroPhage Pharmaceuticals just reported positive results in a pre-clinical study using their anti-protein aggregate therapy, NPT001. Neurophage tested NPT001 in a pre-clinical model of Parkinson’s disease. In this model, NPT001, was able to clear the -synuclein protein aggregates, as well as restore normal function to neurons. The studies were performed in the laboratory of Dr. Eliezer Masliah, a professor at the University of California San Diego. NeuroPhage is one of the newest teams competing for the $1M ALS Treatment Prize, and hopefully, they will reproduce this positive result with NPT001 in ALS!

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail